Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
N Engl J Med. 2019.
PMID: 30516102
Clinical Trial.